Skip to content
Oncology Research Hub

Cincinnati, Ohio

Cancer clinical trials in Cincinnati, OH

154 cancer studies are recruiting participants at sites in Cincinnati as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cincinnati at a glance

  • 154 studies are recruiting at a site in Cincinnati.
  • By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (22), Phase 2 (30), Phase 2/3 (3), Phase 3 (57), Phase 4 (2), No phase (4), Observational (20). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (88), university, hospital or other (56), government (10).
  • By research area: Lymphoma (48), Lung Cancer (41), Breast Cancer (27), Prostate Cancer (19), Pancreatic Cancer (11), Melanoma (8).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Cincinnati

Basic details from each study's public record (the 30 most recently updated of 154). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    The Christ Hospital · University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT03418961 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Good Samaritan Hospital - Cincinnati
    Registry record
    NCT05564377 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
    Registry record
    NCT06966700 · updated
  4. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
    Registry record
    NCT03723928 · updated
  5. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
    Registry record
    NCT05334069 · updated
  6. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study sites
    Good Samaritan Hospital · Oncology Hematology Care, Inc.
    Registry record
    NCT05633654 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Lung cancer studies recruiting in Cincinnati

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT06287775 · updated
  2. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
    Registry record
    NCT06345729 · updated
  3. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Oncology Hematology Care
    Registry record
    NCT06646276 · updated
  4. Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

    • Phase 2
    • Ages 1 to 18
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Cinn Children Hosp Medical Center
    Registry record
    NCT07354074 · updated
  5. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06561386 · updated
  6. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center ( Site 0119)
    Registry record
    NCT06623422 · updated
  7. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Oncology_Hematology Care Clinical Trials,LLC
    Registry record
    NCT07144280 · updated
  8. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    The Christ Hospital
    Registry record
    NCT07361497 · updated
  9. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT07491497 · updated
  10. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT04181060 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Prostate cancer studies recruiting in Cincinnati

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati
    Registry record
    NCT04423211 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Oncology Hematology Care Incorporated
    Registry record
    NCT04221542 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Melanoma studies recruiting in Cincinnati

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Lymphoma studies recruiting in Cincinnati

  1. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    University of Cincinnati
    Registry record
    NCT07221500 · updated
  2. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Cincinnati Children's Hospital
    Registry record
    NCT06173518 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002)
    Registry record
    NCT06717347 · updated
  4. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center ( Site 0156)
    Registry record
    NCT06890884 · updated
  5. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT03739814 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT05675410 · updated
  8. A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 1 and older
    • All sexes
    Sponsor
    Memorial Sloan Kettering Cancer Center
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT07223021 · updated
  9. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT06649812 · updated
  10. A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

    • Phase 1/2
    • From 6 months, up to 30 years
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT05533775 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Cincinnati

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT07562152 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Ask about studies near Cincinnati

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call